RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
0.9912
-0.0088 (-0.88%)
Mar 31, 2025, 2:29 PM EDT - Market open
RenovoRx Employees
RenovoRx had 8 employees as of December 31, 2023. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,145,375
Market Cap
35.25M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | -1 | -11.11% |
| Dec 31, 2022 | 9 | 3 | 50.00% |
| Dec 31, 2021 | 6 | -3 | -33.33% |
| Dec 31, 2020 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RNXT News
- 3 days ago - RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting - Business Wire
- 5 days ago - RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting - Business Wire
- 11 days ago - RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET - Business Wire
- 12 days ago - RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025 - Business Wire
- 4 weeks ago - RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders - Business Wire
- 6 weeks ago - RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery - Business Wire
- 6 weeks ago - RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire
- 7 weeks ago - RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire